Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Regeneron Pharmaceuticals Inc (REGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Regeneron Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
985.02 +4.45    +0.45%
- Closed. Currency in USD ( Disclaimer )
After Hours
985.02
0.00
0.00%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 259,277
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 983.16 - 995.41
Regeneron Pharma 985.02 +4.45 +0.45%

Regeneron Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Regeneron Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

13450

Equity Type

ORD

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Contact Information

Address 777 Old Saw Mill River Road
Tarrytown, 10591-6707
United States
Phone 914 847 7000
Fax -

Top Executives

Name Age Since Title
Joseph L. Goldstein 83 1991 Independent Director
George D. Yancopoulos 63 1998 Co-Founder, President, Chief Scientific Officer & Co-Chairman
Leonard S. Schleifer 70 1988 Co-Founder, President, CEO & Co-Chairman
George L. Sing 74 1988 Independent Director
Michael S. Brown 82 1991 Independent Director
Arthur Frederick Ryan 80 2003 Independent Director
Huda Y. Zoghbi 68 2016 Independent Director
Christine Ann Poon 71 2010 Lead Independent Director
Bonnie L. Bassler 61 2016 Independent Director
N. Anthony Coles 63 2017 Independent Director
Craig B. Thompson 70 2022 Independent Director
David P. Schenkein 66 2023 Director
Kathryn W. Guarini - 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

REGN Comments

Write your thoughts about Regeneron Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
양 한
양 한 Aug 24, 2023 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Scd411 is imminent
Avi Kalo
Avi Kalo Feb 03, 2023 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
REGN Earnings are wrong !!! it was 3.41B not M
borat smagadijev
borat smagadijev Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling knife
Petet Larkar
Petet Larkar Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I want your ******
Carmen Esparza
Carmen Esparza Jan 10, 2022 2:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eliav Biton
Eliav Biton Nov 17, 2021 1:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
best opportunity in this market
Financial Advisors
Financial Advisors Nov 04, 2021 6:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
only take long positions .
David Lousada
David Lousada Nov 04, 2021 6:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
huge earnings beat!
Richard Senato
Richard Senato Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats happening
Marut Patphol
Marut Patphol Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fall
ken ken
ken ken Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Most of sales in this quarters are from COVID, and competion announced results
York Regent
York Regent Aug 05, 2021 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Acquiring Inovio will propel REGN closer to COVID 19 vaccine and clear path to 1K a share.
York Regent
York Regent Aug 05, 2021 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This should boost Inovio. Time to pile up.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email